U.S. FDA GRANTS LIPOGEMS® SECOND IDE APPROVAL FOR A CLINICAL TRIAL ON THE TREATMENT FOR KNEE OA

Contributed by: PR Newswire

Tags

Lipogems-IDE-Approval

More Like This

(Graphic: Business Wire)

4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients

Varian Announces CE Mark for Embozene in Genicular Artery Embolisation, Expanding Treatment for Knee Osteoarthritis

(Photo: Business Wire)

4Moving Biotech Completes the Recruitment of Its Phase I Clinical Trial in Patients With Knee Osteoarthritis

World’s First Patients Successfully Treated With Novel Scarcell Therapeutics Therapy Using Gum Cells Designed to Relieve Knee Osteoarthritis

Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis

PR Newswire associated0

Guerbet announces an important milestone achievement in the "Vascular Embolization" indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil)

PK MED Announces FDA Clearance to Initiate Its Clinical Program for PKM-01, for Local Treatment of Gout Flares, Directly by a Phase 2 Trial